Methods: We determined antibody to hepatitis B surface antigen (anti-HBs) at 4-13 years of age in 363 low risk children who had been vaccinated starting at birth with hepatitis B vaccine.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus ... either positive for the HBV surface antigen (HBsAg) or HBV core antibody (anti-HBc).

By Dr. Liji Thomas, MD New recommendations address advances in immunosuppressive therapies and highlight antiviral prophylaxis for high-risk patients. Study: AGA Clinical Practice Guideline on the ...

Brelovitug (BJT-778) is a fully human immunoglobulin G1 monoclonal antibody designed to target hepatitis B surface antigen and neutralize and remove HBV and HDV virions. The company reports that ...

Single-dose administration of E6F6 could profoundly suppress the levels of hepatitis B surface antigen (HBsAg ... and only forms a smaller antibody–viral particle immune complex with limited ...

Accumulating evidence suggests that the proteins encoded by HBV (hepatitis B surface antigen, hepatitis B core antigen ... the outcome of infection is ultimately determined by HBV-specific antibody ...

Anti-hepatitis B surface antigen antibody; anti-HBc, antibody to hepatitis B core antigen; anti-HBe, Hepatitis B E antibody; HBV DNA, hepatitis B virus deoxyribonucleic acid; PRISMA, Preferred ...